-
MITSUBISHI TANABE PHARMA CORPORATION et al v. INVAGEN PHARMACEUTICALS, INC., DC
- 3:17-cv-06375
- D.N.J.
- Filed: 08/23/2017
- Closed: 06/10/2019
- Latest Docket Entry: 06/01/2020
- Judge: Freda L. Wolfson
+1
- PACER
5
Plaintiffs
1
Defendant
3
Accused
Products
1
Patent-in-Suit
657
Days in
Litigation
-
MITSUBISHI TANABE PHARMA CORPORATION et al v. INVAGEN PHARMACEUTICALS, INC., DC
- 3:17-cv-06375
- D.N.J.
- Filed: 08/23/2017
- Closed: 06/10/2019
- Latest Docket Entry: 06/01/2020
- Judge: Freda L. Wolfson
+1
- PACER
Cause of Action
Infringement
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
-
Infringement
Aurobindo Pharma USA Incorporated
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic 150 mg/500 mg canagliflozin and metformin hydrochloride tabletsGeneric 50 mg/1 g canagliflozin and metformin hydrochloride tabletsGeneric 50 mg/500 mg canagliflozin and metformin hydrochloride tablets | US 7,943,788 B2 | All Asserted Claims |
Infringement
Entry 24
|
Invagen Pharmaceuticals Incorporated
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic 150 mg/500 mg canagliflozin and metformin hydrochloride tabletsGeneric 50 mg/1 g canagliflozin and metformin hydrochloride tabletsGeneric 50 mg/500 mg canagliflozin and metformin hydrochloride tablets | US 7,943,788 B2 | All Asserted Claims |
Infringement
Entry 37
|